Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Financials | Market Cap | ROE | ROA | ROCE | ROIC | D/E | Current Ratio | Gross Margin | Profit Margin | Operating Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TGTX | TG THERAPEUTICS INC | $7.13B | 12.40% | 4.80% | 10.19% | 11.70% | 1.60 | 6.25 | 88.30% | 7.10% | 15.08% | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.13B | 1.50% | 1.10% | 2.71% | 2.60% | 0.46 | 4.57 | 88.00% | 2.40% | 5.22% | ||
| CORT | CORCEPT THERAPEUTICS INC | $7.54B | 22.70% | 18.70% | 19.36% | 27.00% | 0.24 | 3.35 | 98.40% | 20.70% | 20.07% | ||
| KRYS | KRYSTAL BIOTECH INC | $4.77B | 10.30% | 9.40% | 10.00% | 18.10% | 0.12 | 7.28 | 93.10% | 30.70% | 32.82% | ||
| NAGE | NIAGEN BIOSCIENCE INC | $587.79M | 24.40% | 14.70% | 17.59% | 94.00% | 0.48 | 3.57 | 61.80% | 8.60% | 8.89% | ||
| SPRY | ARS PHARMACEUTICALS INC | $1.39B | 3.60% | 3.10% | 2.53% | 3.90% | 0.37 | 14.26 | 98.90% | 9.00% | 9.29% | ||
| GYRE | GYRE THERAPEUTICS INC | $874.34M | 19.90% | 9.80% | 16.44% | 19.90% | 0.43 | 3.32 | 96.30% | 11.40% | 16.46% | ||
| ARGX | ARGENX SE | $38.88B | 17.40% | 15.50% | 1.58% | 3.00% | 0.13 | 7.29 | -5,127.40% | 19,159.20% | 2,015.73% | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.95B | 25.60% | 22.00% | 29.60% | 330.80% | 0.17 | 5.17 | 86.00% | 33.30% | 43.98% | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.71B | 25.20% | 16.00% | 25.40% | 47.70% | 0.52 | 3.31 | 78.10% | 20.40% | 29.28% | ||
| VCEL | VERICEL CORP | $1.89B | 4.00% | 2.70% | 2.91% | 3.10% | 0.48 | 4.23 | 72.60% | 4.40% | 4.69% | ||
| EXEL | EXELIXIS INC | $10.88B | 23.80% | 18.20% | 26.79% | 28.50% | 0.31 | 3.64 | 96.50% | 24.00% | 31.43% | ||
| SRPT | SAREPTA THERAPEUTICS INC | $6.09B | 19.70% | 6.60% | 8.07% | 7.00% | 1.59 | 4.20 | 83.20% | 12.40% | 13.71% | ||
| HALO | HALOZYME THERAPEUTICS INC | $7.39B | 138.40% | 22.20% | 29.89% | 24.20% | 4.67 | 7.80 | 84.30% | 43.70% | 56.65% | ||
| RIGL | RIGEL PHARMACEUTICALS INC | $334.39M | -95.90% | 12.50% | 26.11% | 39.20% | 48.87 | 2.13 | 89.60% | 9.80% | 14.66% | ||
| RPRX | ROYALTY PHARMA PLC | $18.72B | 8.50% | 4.90% | 6.39% | 4.70% | 0.76 | 1.44 | 100.00% | 37.90% | 47.91% | ||
| NVO | NOVO NORDISK A S | $292.90B | 85.00% | 26.40% | 51.23% | 87.20% | 2.25 | 0.74 | 84.70% | 34.80% | 43.80% | ||
| ADMA | ADMA BIOLOGICS INC | $5.53B | 85.70% | 49.20% | 32.24% | 37.00% | 0.40 | 5.97 | 51.50% | 46.40% | 32.75% | ||
| INCY | INCYTE CORP | $12.01B | 0.60% | 0.40% | 7.87% | 16.30% | 0.57 | 2.04 | 92.70% | 0.50% | 7.19% | ||
| MDXG | MIMEDX GROUP INC | $933.48M | 21.60% | 15.90% | 23.50% | 50.80% | 0.33 | 4.70 | 81.90% | 11.40% | 15.19% | ||
| MNKD | MANNKIND CORP | $1.50B | -14.80% | 6.20% | 21.95% | 9.90% | -6.00 | 3.28 | 73.20% | 9.70% | 23.99% | ||
| VCYT | VERACYTE INC | $2.32B | 2.10% | 1.90% | 2.11% | 24.60% | 0.11 | 4.73 | 66.90% | 5.40% | 5.78% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.96B | 8.00% | 6.10% | 8.69% | 9.90% | 0.24 | 5.33 | 79.70% | 15.00% | 19.43% | ||
| GNFT | GENFIT SA | $203.98M | 2.20% | 0.90% | 8.68% | 15.10% | 1.19 | 1.23 | 100.00% | 2.10% | 9.33% | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $7.12B | 14.20% | 4.80% | 6.44% | 9.10% | 1.93 | 4.46 | 89.00% | 13.80% | 17.37% | ||
| TECH | BIO-TECHNE CORP | $7.85B | 7.60% | 5.80% | 8.03% | 14.90% | 0.29 | 3.94 | 65.60% | 13.20% | 16.85% | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $2.43B | 39.50% | 23.00% | 32.55% | 75.00% | 0.62 | 2.38 | 91.50% | 23.60% | 26.94% | ||
| GMAB | GENMAB A | $13.85B | 23.80% | 19.50% | 27.51% | 64.30% | 0.25 | 5.25 | 95.40% | 36.40% | 51.76% | ||
| UTHR | UNITED THERAPEUTICS CORP | $13.25B | 19.30% | 16.70% | 22.78% | 31.60% | 0.14 | 5.46 | 89.00% | 40.40% | 53.43% | ||
| REGN | REGENERON PHARMACEUTICALS INC | $63.70B | 15.50% | 12.10% | 14.81% | 15.40% | 0.28 | 4.93 | 85.80% | 31.90% | 35.72% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.